摘要
In the past few decades,tremendous advances have been made in terms of advaneed non-small cell lung cancer(NSCLC).The identification of oncogenic drivers and the development of targeted therapies led to the development of"pre&sion"medicine.On the other hand,more attention has been paid to cancer immune escape and a new class of immunomodulatory agents has been developed.It is very attractive to explore the combination strategies of the two approaches,which may also be meaningful from the perspective of immunology.
基金
the grants from the National Natural Science Foundation of China(No.81672896)
the National Key Research and Development Program:The key technology of palliative care and nursing for cancer patients(No.ZDZX2017ZL-01)
High Level Innovation Team of Nanjing Medical University(No.JX102GSP201727).